Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia

Aimaz Afrough; Jin Seon Im; Nitin Jain; Partow Kebriaei

doi:10.1016/B978-0-323-79833-4.00016-4

Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia

Aimaz Afrough, Jin Seon Im, Nitin Jain, Partow Kebriaei

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Novel immunotherapies are changing the treatment landscape for patients with acute lymphoblastic leukemia (ALL). Specifically, chimeric antigen receptor (CAR) T-cell therapy results in response rates up to 90% in patients with previously refractory disease. We will review the U.S. Food and Drug Administration approved CAR T therapies in ALL, as well as the unique considerations for CAR T manufacture, administration, and toxicity profile. Finally, we will review CAR T products targeting antigens other than CD19, and allogeneic CAR T products under investigation.

Original language	English (US)
Title of host publication	Manual of Hematopoietic Cell Transplantation and Cellular Therapies
Publisher	Elsevier
Pages	233-245
Number of pages	13
ISBN (Electronic)	9780323798334
ISBN (Print)	9780323798341
DOIs	https://doi.org/10.1016/B978-0-323-79833-4.00016-4
State	Published - Jan 1 2023

Keywords

acute lymphoblastic leukemia
CAR T-cell
indications
outcome

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-323-79833-4.00016-4

Cite this

@inbook{f4e2434249b34f2da9848d1c1874d3b1,

title = "Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia",

abstract = "Novel immunotherapies are changing the treatment landscape for patients with acute lymphoblastic leukemia (ALL). Specifically, chimeric antigen receptor (CAR) T-cell therapy results in response rates up to 90% in patients with previously refractory disease. We will review the U.S. Food and Drug Administration approved CAR T therapies in ALL, as well as the unique considerations for CAR T manufacture, administration, and toxicity profile. Finally, we will review CAR T products targeting antigens other than CD19, and allogeneic CAR T products under investigation.",

keywords = "acute lymphoblastic leukemia, CAR T-cell, indications, outcome",

author = "Aimaz Afrough and Im, {Jin Seon} and Nitin Jain and Partow Kebriaei",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-79833-4.00016-4",

language = "English (US)",

isbn = "9780323798341",

pages = "233--245",

booktitle = "Manual of Hematopoietic Cell Transplantation and Cellular Therapies",

publisher = "Elsevier",

}

TY - CHAP

T1 - Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia

AU - Afrough, Aimaz

AU - Im, Jin Seon

AU - Jain, Nitin

AU - Kebriaei, Partow

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Novel immunotherapies are changing the treatment landscape for patients with acute lymphoblastic leukemia (ALL). Specifically, chimeric antigen receptor (CAR) T-cell therapy results in response rates up to 90% in patients with previously refractory disease. We will review the U.S. Food and Drug Administration approved CAR T therapies in ALL, as well as the unique considerations for CAR T manufacture, administration, and toxicity profile. Finally, we will review CAR T products targeting antigens other than CD19, and allogeneic CAR T products under investigation.

AB - Novel immunotherapies are changing the treatment landscape for patients with acute lymphoblastic leukemia (ALL). Specifically, chimeric antigen receptor (CAR) T-cell therapy results in response rates up to 90% in patients with previously refractory disease. We will review the U.S. Food and Drug Administration approved CAR T therapies in ALL, as well as the unique considerations for CAR T manufacture, administration, and toxicity profile. Finally, we will review CAR T products targeting antigens other than CD19, and allogeneic CAR T products under investigation.

KW - acute lymphoblastic leukemia

KW - CAR T-cell

KW - indications

KW - outcome

UR - http://www.scopus.com/inward/record.url?scp=85167774937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85167774937&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-79833-4.00016-4

DO - 10.1016/B978-0-323-79833-4.00016-4

M3 - Chapter

AN - SCOPUS:85167774937

SN - 9780323798341

SP - 233

EP - 245

BT - Manual of Hematopoietic Cell Transplantation and Cellular Therapies

PB - Elsevier

ER -

Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this